SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Wockhardt secures USFDA’s approval for ZAYNICH

01 Jun 2026 Evaluate

Wockhardt has secured U.S. Food and Drug Administration’s (USFDA) approval for ZAYNICH (cefepime and zidebactam), a novel intravenous antibiotic for the treatment of adults with complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Gram-negative pathogens. ZAYNICH previously received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the USFDA. ZAYNICH is the first New Chemical Entity fully developed and commercialized by an Indian pharmaceutical company to receive an USFDA approval.

The USFDA approval was based, in part, on the results from ENHANCE-1, a Phase 3, randomized, double-blind, multicenter study which evaluated the efficacy, safety and tolerability of ZAYNICH compared with meropenem in the treatment of hospitalized adults with cUTI or acute pyelonephritis (AP). ZAYNICH demonstrated efficacy at the primary endpoint, achieving a composite clinical cure and microbiological response rate of 89.0% versus 68.4% for meropenem Treatment difference 20.6% (95% CI; 12.3, 29.5). ZAYNICH was generally well tolerated in the phase 3 study. The study enrolled 530 patients from the U.S., Europe, LATAM, China and India, and spanned across 64 sites.

ZAYNICH was approved by the Drugs Controller General of India (DCGI) on May 27, 2026. The company has also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency.

Wockhardt is a research based Global Pharmaceutical and Biotech company.

Wockhardt Share Price

2072.95 -6.00 (-0.29%)
04-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1779.35
Dr. Reddys Lab 1267.05
Cipla 1397.75
Zydus Lifesciences 1085.45
Lupin 2248.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×